trial

Kuvan in People With Schizophrenia and Schizoaffective Disorder

NCTId NCT01706965
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Completed
Enrollment 27 (actual)
Sponsored by New York State Psychiatric Institute, Washington Heights Community Service
Primary completion 2016-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Completed
Enrollment
27 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2012-10
Primary completion
2016-06
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
KuvanMultivitamin

Sponsors

New York State Psychiatric Institute, Washington Heights Community ServiceLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

1
Jeffrey A Lieberman, M.D.Principal Investigator

Sites

1 total
New York, United States

Linked catalysts

1
Kuvan in People With Schizophrenia and Schizoaffective Disorder — primary completion2016-06

Facts & assertions

4 sourced
Enrollment
27
Phase
PHASE1,PHASE2
Primary Completion Date
2016-06
Status
COMPLETED
relationships
The graph out of here
drug
Kuvan
drug
Multivitamin
drug
lead_sponsor
New York State Psychiatric Institute, Washington Heights Community Service
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Jeffrey A Lieberman, M.D.
person